Compare DexCom, Inc. (DXCM) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nebius Group NV — how do they compare? DexCom, Inc. trades at $77.92 (market cap $28.06B), while Nebius Group NV trades at $175.6 (market cap $50.66B). The key difference: Nebius Group NV is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| DXCM | NBIS | |
|---|---|---|
Market Cap | $28.06B | $50.66B |
Sector | Health | Technology |
52-Week High | $89.53 | $286.69 |
52-Week Low | $54.84 | $50.40 |
Enterprise Value | $27.03B | $50.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Nebius (NBIS) trades at $186.67, down 3.76% for the day amid a bearish technical signal. The stock shows mixed earnings performance with recent beats but a Q4 2025 miss, while analyst consensus remains strongly bullish with an $248 price target. Recent news highlights a $1 billion compute deal with Reflection AI and expansion of its AI cloud platform through infrastructure partnerships, signaling strong demand growth.
The outlook for NBIS is positive based on robust AI infrastructure demand and strategic expansions, though high valuation multiples and competitive pressures from tech giants like Meta pose risks. Cash flow trends show significant investing outflows funded by financing, supporting aggressive growth but requiring careful execution to maintain shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
